Mycoplasma pneumoniae Encephalopathy: Recovery After Intravenous Immunoglobulin

Attilakos, Achilleas; Palaiologou, Penelope; Lagona, Evagelia; Voutsioti, Aikaterini; Dinopoulos, Argirios

doi:10.1016/j.pediatrneurol.2008.01.003

Cited by 12 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yun et al reported that IVIG therapy was beneficial for patients with pneumonia, including MP pneumonia, who did not respond to initial antibiotic therapy [ 28 ]. Some investigators have used IVIG for extrapulmonary manifestations of MP infection, including encephalopathy, rhabdomyolysis and hemolytic anemia [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Early Additional Immune-Modulators forMycoplasma pneumoniaePneumonia in Children: An Observation Study

et al. 2014

View full text Add to dashboard Cite

BackgroundMycoplasma pneumoniae (MP) pneumonia is a self-limiting disease, but some patients complain of progressive pneumonia, despite of appropriate antibiotic treatment. We aimed to introduce the role of immune-modulators (corticosteroid and/or intravenous immunoglobulin, IVIG) treatment for childhood MP pneumonia based on previous our experiences.Materials and MethodsA retrospective case series analysis for 183 children with MP pneumonia was performed. MP pneumonia patients were diagnosed by two Immunoglobulin M (IgM) tests: the micro-particle agglutination method (≥1:40) and the cold agglutination test (≥1:4), and were examined twice at the initial admission and at discharge. Among 183 MP pneumonia patients, 90 patients with persistent fever for over 48 hours after admission or those with severe respiratory symptoms and signs received additional prednisolone (82 patients, 1 mg/kg/day) or intravenous methylprednisolone (8 patients, 5-10 mg/kg/day) with antibiotics. Four patients with aggravated clinical symptoms and chest radiographic findings after corticosteroid treatment received IVIG (1 g/kg/day, 1-2 doses).ResultsMean age of 183 patients was 5.5 ± 3.2 years (6 months-15 years), and the male: female ratio was 1.1:1 (96:87). Fifty-seven patients (31%) were seroconverters and 126 seropositive patients showed increased diagnostic IgM antibody titres during admission (over 4 folds). The majority of the patients who received corticosteroids (86/90 cases) showed rapid defervescence within 48 hours with improved clinical symptoms, regardless of the used antibiotics. Also, 4 patients who received additional IVIG improved both clinically and radiographically within 2 days without adverse reaction.ConclusionsIn the era of macrolide-resistant MP strains, early additional immune-modulator therapy with antibiotics might prevent from the disease progression and reduce the disease morbidity without adverse reaction.

show abstract

Section: Discussionmentioning

confidence: 99%

Early Additional Immune-Modulators forMycoplasma pneumoniaePneumonia in Children: An Observation Study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A number of studies have suggested that humoral and cellular immune responses [43,44] contribute to the pathogenesis of MP infection, providing a theoretical basis for the application of immunosuppressive agents such as GC in Mycoplasma pneumonia. Studies have shown that the addition of GC on the basis of the conventional treatment has a de nite effect on RMPP, which contributes to the control of the disease progression, the improvement of the condition and the reduction of sequelae [10,16] .…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy

Zhu

Zhang

Guo

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: To observe the effect of corticosteroids in the treatment of children with refractory Mycoplasma pneumoniae pneumonia(RMPP) under different doses, to summarize the clinical features of children treated with glucocorticoid pulse therapy.Methods: The clinical data of 125 children with RMPP hospitalized in Tianjin Children's Hospital from September 2018 to October 2019 were retrospectively analyzed. They were divided into two groups according to the dose of hormone. Compare the clinical features, laboratory findings, and imaging between the two groups of children, and use meaningful related indicators as ROC curves to find reference indicators for pulse therapy.Results: (1)The median age of the group II was older than that of the group I(P<0.05).(2)We found more severe presentations, higher incidence of extra-pulmonary complications and more serious radiological findings in group II, which needed oxygen more often, higher the hormone amount, higher usage rate of gamma globulin, higher usage rate of bronchoscopy, and higher incidence of plastic bronchitis(P<0.05).(3)WBC, CRP, LDH, FER, D-D dimer, APTT, TT, PCT, IL-6 and the percentage of neutrophils in peripheral blood in Group II were higher than those in Group I(P<0.05).(4)In ROC curve analysis, CRP, LDH, FER, and neutrophils of leukocyte classification were independent related factors that could be used as valuable predictors of methylprednisolone pulse therapy for RMPP in children. The cut-off values were CRP44.45mg/L, LDH590IU/L, FER411ng/L, and neutrophils in leukocyte classification were 73.75%, respectively.Conclusion: CRP≥44.45mg/L, LDH≥590IU/L, FER≥411ng/L, neutrophil≥73.75%, lung consolidation and pleural effusion are found in RMPP patients, which should be treated with pulse dose of methylprednisolone in time to reduce the incidence of severe RMPP and the occurrence of severe sequelae.

show abstract

“…A number of studies have suggested that humoral and cellular immune responses [43,44] contribute to the pathogenesis of MP infection, providing a theoretical basis for the application of immunosuppressive agents such as glucocorticoids in Mycoplasma pneumonia. Studies have shown that the addition of GCs on the basis of the conventional treatment has a de nite effect on RMPP, which contributes to the control of the disease progression, the improvement of the condition and the reduction of sequelae [10,16] .…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy

Zhu

Zhang

Guo

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: To observe the effect of corticosteroids in the treatment of children with refractory Mycoplasma pneumoniae pneumonia (RMPP) under different doses, to summarize the clinical features of children treated with glucocorticoid pulse therapy.Methods: The clinical data of 125 children with RMPP hospitalized in Tianjin Children's Hospital from September 2018 to October 2019 were retrospectively analyzed. They were divided into two groups according to the dose of hormone. Compare the clinical features, laboratory findings, and imaging between the two groups, and use meaningful related indicators as ROC curves to find reference indicators for pulse therapy.Results: (1)The median age of the group II was older than that of the group I(P<0.05).(2)We found more severe presentations, higher incidence of extra-pulmonary complications and more serious radiological findings in group II, which needed oxygen more often, higher the hormone, higher usage rate of gamma globulin, higher usage rate of bronchoscopy, and higher incidence of plastic bronchitis(P<0.05).(3)WBC, CRP, LDH, FER, D-D dimer, APTT, TT, PCT, IL-6 and the percentage of neutrophils in peripheral blood in Group II were higher than those in Group I(P<0.05).(4)In ROC curve analysis, CRP, LDH, FER, and neutrophils of leukocyte classification were independent related factors that could be used as valuable predictors of methylprednisolone pulse therapy for RMPP in children. The cut-off values were CRP44.45mg/L, LDH590IU/L, FER411ng/L, and neutrophils in leukocyte classification were 73.75%, respectively.Conclusion: CRP≥44.45mg/L, LDH≥590IU/L, FER≥411ng/L, neutrophil≥73.75%, lung consolidation and pleural effusion are found in RMPP patients, which could be treated with pulse dose of methylprednisolone in time to reduce the incidence of severe RMPP and the occurrence of severe sequelae.

show abstract

Mycoplasma pneumoniae Encephalopathy: Recovery After Intravenous Immunoglobulin

Cited by 12 publications

References 14 publications

Early Additional Immune-Modulators forMycoplasma pneumoniaePneumonia in Children: An Observation Study

Early Additional Immune-Modulators forMycoplasma pneumoniaePneumonia in Children: An Observation Study

Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy

Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy

Contact Info

Product

Resources

About